NA
NAGE

Navellier & Associates’s Niagen Bioscience NAGE Stock Holding History

Navellier & Associates’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-164,782
Closed -$1.05M – 369
2025
Q4 		$1.05M Sell
164,782
-24,752
-13% -$172K 0.12% 147
2025
Q3 		$1.77M Buy
189,534
+37,461
+25% +$378K 0.18% 124
2025
Q2 		$2.19M Buy
152,073
+27,015
+22% +$267K 0.27% 95
2025
Q1 		$1.06M Buy
+125,058
New +$786K 0.15% 130

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Navellier & Associates's NAGE Position: Q1 2026 in Review

Navellier & Associates sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 164,782 shares — an estimated $1.05M sold.

Navellier & Associates first reported a position in NAGE in Q1 2025 and held it in 4 quarters. The position peaked at $2.19M in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Navellier & Associates reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Navellier & Associates sold 164,782 Niagen Bioscience shares in Q1 2026, an estimated $1.05M.
  • Navellier & Associates first reported a position in Niagen Bioscience in Q1 2025 and held it in 4 quarters.
  • Navellier & Associates's Niagen Bioscience position peaked at $2.19M in Q2 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Navellier & Associates's 13F filing for Q1 2026, filed 7 May 2026.